• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Long ‐term experience with intranasal bevacizumab therapy
ConclusionsIntranasal bevacizumab injection is an effective treatment for most of the moderate and severe grades of HHT‐associated epistaxis. The duration of the effect of the treatment was variable. Primary and late resistance phenomena to the treatment were quite common. Level of Evidence4. Laryngoscope, 2018
Source: The Laryngoscope - February 22, 2018 Category: ENT & OMF Authors: Johan Steineger, Terje Osnes, Ketil Heimdal, Sinan Dheyauldeen Tags: Allergy/Rhinology Source Type: research

Pazopanib effective for bevacizumab ‐unresponsive epistaxis in hereditary hemorrhagic telangiectasia
We describe a patient with HHT with epistaxis recalcitrant to several endonasal procedures and six cycles of intravenous bevacizumab, for which he was dependent on iron infusions and packed red blood cells transfusions. He then started pazopanib at 100 mg with dramatic improvements in epistaxis and normalization of hemoglobin and iron levels, without replenishment needs for 12 months. This is the first report on the efficacy of pazopanib with high selectivity for abrogating VEGF receptor‐2 signaling in HHT, and needs to be explored further. Laryngoscope, 2018
Source: The Laryngoscope - February 16, 2018 Category: ENT & OMF Authors: Joseph G. Parambil, Troy D. Woodard, Omer N. Koc Tags: Allergy/Rhinology Source Type: research

Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report
Intranasal bevacizumab injections have been used in treating hereditary hemorrhagic telangiectasia (HHT)‐related epistaxis since 2009. It is believed to be a safe and effective treatment for a selected group of HHT patients in reducing frequency and intensity of epistaxis, with few or none adverse effects. In this case report, however, we will describe a patient who developed bilateral osteonecrosis in the knees while undergoing regular intranasal submucosal bevacizumab injections. Although osteonecrosis previously has been documented in patients receiving bevacizumab intravenously in oncologic doses, thus far it has not...
Source: The Laryngoscope - July 3, 2017 Category: ENT & OMF Authors: Johan Steineger, Else Merckoll, John Magnar Sl åstad, Erik Fink Eriksen, Ketil Heimdal, Sinan Dheyauldeen Tags: Allergy/Rhinology Source Type: research